Evidence showed that, compared to those with normal renal function, serum levels of sclerostin started to increase from CKD stage III and progressively increased to two to four times higher as renal function progressed to ESRD needing dialysis [28,29]. This evidence concerns the gene SOST and chronic kidney disease.